Nykredit A/S’s Madrigal Pharmaceuticals MDGL Stock Holding History

Nykredit A/S’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$356K	Buy	+663	New	+$340K	﹤0.01%	792

Other funds holding MDGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Nykredit A/S's MDGL Position: Q2 2026 in Review

Nykredit A/S opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 663 shares worth $356K. The stake represents ﹤0.01% of the portfolio and ranks #792 among its holdings.

281 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Nykredit A/S held 663 shares of Madrigal Pharmaceuticals worth $356K as of Q2 2026.
Madrigal Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #792 holding.
281 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.